---
title: "Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Long-term morbidity"
description: "Formulary evidence on Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Long-term morbidity. Topics: Long-term disability and loss of ambulation, Use of mobility aids, Treatment delay and accumulation of irreversible disability, Refractory disease despite standard-of-care therapy, and 1 further topic. 5 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description/long-term-morbidity"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Long-term morbidity

<a id="heading-2.2.1.7"></a>

## 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

### Long-term disability and loss of ambulation

> “The pooled fraction of nonambulatory patients was 8.2% (95% CI, 5.7% to 11.6%) and, overall, 47.1% (95% CI, 39.5% to 54.9%) of CIDP patients had a good outcome without disability.”

Source: [Al-Zuhairy and Jakobsen (2023)](https://pubmed.ncbi.nlm.nih.gov/36928889/)

> “Disability and isokinetic strength were impaired by 17% and 20%, respectively, as compared with matched control subjects.”

Source: [Al-Zuhairy et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31793666/)

> “Among the subtypes, typical CIDP had the most severe disability before treatment (44% of patients could not walk independently).”

Source: [Aotsuka et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38408295/)

<a id="topic-2.2.1.7-2"></a>

### Use of mobility aids

> “Overall, 47.3% of patients with CIDP (ranging from 41.7% in Japan and 50.0% in China) were recorded to use mobility aids at the time of data collection. Across all regions, a cane/walking stick was used by 35.3% of patients, followed by the wheeled walker (8.0%), walking frame, and/or manual wheelchair (both 4.9%)”

Source: [Querol et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12361836/)

<a id="topic-2.2.1.7-3"></a>

### Treatment delay and accumulation of irreversible disability

> “Prolongation of time until start of therapy was associated with an increased burden of long-term disability.”

Source: [Al-Zuhairy et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31793666/)

> “Treatment initiation within 1 year of onset was significantly associated with lesser post‐treatment disability and greater amplitude of treatment response, in each cohort separately, and in the combined cohort.”
> “Early treatment initiation is a key modifiable determinant of favorable long‐term disability in CIDP. These findings underscore the importance of timely diagnosis and prompt treatment to prevent irreversible axonal damage.”

Source: [Min et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11628630/)

> “Patients who started their initial treatment later experienced a worsening disease course, as reflected by a significant deterioration in their Inflammatory Neuropathy Cause and Treatment (INCAT) leg disability score.”

Source: [Quint et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11377626/)

<a id="topic-2.2.1.7-4"></a>

### Refractory disease despite standard-of-care therapy

> “Overall, 110 (56%) patients responded to their first therapy and were thus assigned to the status SOC-responder”
> “76 (39%) patients did not respond to their first therapy and were assigned to the status SOC-refractory”
> “SOC-refractory patients had worse clinical outcomes than SOC-responders. Associated factors for SOC-refractory status included the presence of fatigue as a symptom and alcohol dependence.”

Source: [Quint et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11377626/)

<a id="topic-2.2.1.7-5"></a>

### Cancer risk compared with the general population

> “The observed number of cancer diagnoses corresponded to an incidence rate of 5.63%, with a standardized incidence ratio (SIR) of 2.83 (95% confidence interval [CI]: 1.89–4.39) compared to the expected cancer incidence rate of 2.00%.”

Source: [Choi et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11390450/)

## Related pages
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: References](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references.md)
